Fmr LLC increased its holdings in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 11.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,603,622 shares of the biopharmaceutical company’s stock after acquiring an additional 159,218 shares during the period. Fmr LLC owned about 1.17% of Achillion Pharmaceuticals worth $7,361,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Cambridge Investment Research Advisors Inc. lifted its stake in Achillion Pharmaceuticals by 3.6% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 800 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Achillion Pharmaceuticals by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 457,341 shares of the biopharmaceutical company’s stock worth $2,100,000 after acquiring an additional 2,850 shares in the last quarter. Bank of Montreal Can lifted its stake in Achillion Pharmaceuticals by 6.4% in the 2nd quarter. Bank of Montreal Can now owns 56,715 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 3,410 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Achillion Pharmaceuticals by 1.8% in the 2nd quarter. Wells Fargo & Company MN now owns 219,647 shares of the biopharmaceutical company’s stock worth $1,009,000 after acquiring an additional 3,827 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in Achillion Pharmaceuticals by 18.6% in the 2nd quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 4,144 shares in the last quarter. 74.64% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have recently weighed in on the company. BidaskClub raised Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Maxim Group set a $7.00 price target on Achillion Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Robert W. Baird downgraded Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target for the company. in a research note on Thursday, August 10th. Zacks Investment Research downgraded Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Finally, Chardan Capital cut their price target on Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. Achillion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $6.75.

TRADEMARK VIOLATION WARNING: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://theolympiareport.com/2017/11/02/achillion-pharmaceuticals-inc-achn-shares-bought-by-fmr-llc.html.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.03. During the same period in the prior year, the business posted ($0.15) EPS.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.